EP0667789A1 - Restoration of immunocompetency to t helper cells in hiv infected patients - Google Patents

Restoration of immunocompetency to t helper cells in hiv infected patients

Info

Publication number
EP0667789A1
EP0667789A1 EP93921492A EP93921492A EP0667789A1 EP 0667789 A1 EP0667789 A1 EP 0667789A1 EP 93921492 A EP93921492 A EP 93921492A EP 93921492 A EP93921492 A EP 93921492A EP 0667789 A1 EP0667789 A1 EP 0667789A1
Authority
EP
European Patent Office
Prior art keywords
antibodies
antagonist
helper cells
interleukin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93921492A
Other languages
German (de)
French (fr)
Inventor
Mario Dr. c/o Facolta di Madicina CLERICI
Robert L. Coffman
Gene M. Shearer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Merck Sharp and Dohme Corp
Original Assignee
US Department of Health and Human Services
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Schering Corp filed Critical US Department of Health and Human Services
Publication of EP0667789A1 publication Critical patent/EP0667789A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10

Definitions

  • This invention relates to the use of antagonists against IL-10 for pharmaceutical administration to patients infected with a immunodeficiency virus.
  • the administration of these antagonists restores the ability of T helper cells to produce IL-2.
  • This invention provides methods of increasing the level of IL-2 produced by T helper cells in a patient infected with a human immunodeficiency virus.
  • the method comprises administering an amount of an antagonist of interleukin 10 wherein said amount is effective to increase the patient's T helper cell production of IL-2.
  • the antagonists are preferably administered intravenously.
  • a preferred antagonist is an antibody specific for binding to IL-10.
  • the antibodies can be chimeric, recombinant, polyclonal or monoclonal. Autologous antibodies, human or humanized antibodies are preferred for safety when human patients are being treated.
  • the preferred single dosage of antibodies is 1-10 mg/kg body weight per antibody. Alternatively the amount of the antibody administered in a single dose is about 10 to about 100 ⁇ g per milliliter of patient sera.
  • This invention provides an effective means for increasing production of IL-2 in T helper cells when said levels are being inhibited by excessive levels of IL-10 attendant an infection of lentiviruses known as the human immunodeficiency virus [HIV].
  • HIV human immunodeficiency virus
  • This chronic and often fatal viral infection is typified by an imbalance in T helper cellular responses.
  • the result of this imbalance is an inhibition of IL-2 production by nonvirally infected T helper cells due to excessive levels of IL-10.
  • the IL-10 is produced by a number of different cells including a subset of the T helper cells.
  • IL-2 is responsible for T cell proliferation and is a key indicator of the status of the immune system.
  • Antagonists of IL-10 can be made by mutating the amino acid sequence of IL-10 using standard mutagenesis methods. Such methods include the use of M13 vectors to introduce single site mutations, to delete random amino acids from IL-10 or to add amino acids. The resulting muteins are then tested in standard assays for the ability to compete with nonmutated IL-10. Suitable assays are described below and include in vitro cell assays where IL-2 dependent proliferation is initiated by the presence of exogenous IL-10. This strategy have been used to characterize the functional domains of numerous proteins such as thrombomodulin, human growth factor and tissue plasminogen activator.
  • the antagonist can be an antibody specific for binding to IL-10 [ ⁇ IL-10] and which interferes with its binding to the T- helper receptor, ⁇ IL-10 is produced in a variety of conventional ways.
  • a general review of antibody production can be found in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Pubs., N.Y. (1988) or in Colligan et al. Eds., 1991 and Suppl. Current Protocols in Immunology, Green Wiley, NY, NY.
  • Antibodies can be a polyclonal mixture or monoclonal.
  • Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources. Antibodies also include the immunore active portions of intact immunoglobulins.
  • ⁇ IL-10 antibodies involve administering an amount of antigen sufficient to induce a humoral response in a mammal.
  • the antibodies are either collected from the mammal's sera or lymphocytes removed, immortalized and those cell clones secreting the desired antibodies isolated and cultured for harvest of the desired antibodies.
  • Antibodies against IL-10 are described by Mosmann et al, 1990 /. Immunol. 145:2938.
  • the antigens can either be intact IL-10 or immunoreactive peptides.
  • Recombinant expression of IL-10 is a convenient means for obtaining IL-10 for use as antigens.
  • Specific techniques for expressing and purifying IL-10 are known. Expression of IL-10 is described in PCT/US/03554 (WO/91 /00349) and in Malefyt, et al., 1992, Curr. Opin. Immunology, 4:314-320.
  • peptide synthesis may be used to obtain intact or immunoreactive portions of IL-10.
  • the antibodies for use in this invention are preferably autologous for the patient thereby minimizing further immunological problems. Immunodefi ⁇ ent individuals will tend to be less reactive to non-self antibodies, and thus non-self antibodies derived from cells of the same species are also useful. Antibodies of different species are useful but means to control possible adverse immi oreactions must be undertaken. For example, humanized rat antibodies can minimize immune responses in human patients.
  • the antibodies for use in this invention are typically neutralizing antibodies and will preferably have binding constants which are greater than or approximates the affinity of IL-10 for its natural receptor. Antibodies having a binding constant 100-fold less than these cytokines for their corresponding receptors are less preferred. Binding comparisons are carried out using standard equilibrium methods. The basic technology is described in Chapter 25 of Vol. 1: Immunochemistry, Ed. D.M. Weir, 4th Ed. 1986, Blackwell Scientific Publ. 25. 1-25.30. Alternatively, one can use an assay for determining the molar excess of antibody which neutralizes a defined amount of IL-10 in a standard in vitro bioassay. Examples of such assays are found in Mosmann and Fong, 1989, /. Immunol.
  • the means of adinudistration of the antagonists are typically parenteral, preferably intravenous.
  • the antagonists are infused into the patient using standard intravenous techniques.
  • the antagonists are first suspended into a sterile, physiologically-compatible media, such as phosphate buffered saline.
  • Pharmaceutically acceptable excipients such as lecithin, glucose, dextrose, antibiotics may also be included with the antagonists.
  • the antagonists are antibodies, they are administered in an amount which provides circulating levels of ⁇ IL-10 at about 1 to 150 ⁇ g/ml and preferably 10 to 100 ⁇ g/ml of sera for each antibody.
  • the antibodies have a 2-7 day half -life and repeated administration is necessary when levels of ⁇ IL-10 are below these levels.
  • Total amount of ⁇ IL-10 applied per administration are between 1 and 10 mg/kg of body weight for each antibody.
  • the method will increase IL-2 production and it is preferred that said levels approach or exceed 100% of normal. Increases of greater than 50% of the IL-2 production before treatment are considered good. Treatment can be terminated when the T helper cells are producing levels of IL-2 at 10 to 100% of normal when measured by any number of conventional assays.
  • the first category are bioassays that measure IL-2 dependent proliferation of any of several immortal cell lines which proliferate in the presence of IL-2.
  • An example of such a cell line is CTLL.
  • Cell division is measured by radiolabelled thymidine uptake.
  • the second category are functional assays and involve the use of immunoassays directly measuring IL-2 such as ELISA.
  • ELISA immunoassays directly measuring IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention relates to the use of antagonists to IL-10 such as anti-IL-10 antibodies for pharmaceutical administration to patients infected with an immunodefenciency virus. The administration of these antibodies restores the ability of T helper cells to produce IL-2.

Description

RESTORATION OF IMMUNOCOMPETENCY TO T HELPER CELLS IN
HIV INFECTED PATIENTS
BACKGROUND OF THE INVENTION
Field of the invention. This invention relates to the use of antagonists against IL-10 for pharmaceutical administration to patients infected with a immunodeficiency virus. The administration of these antagonists restores the ability of T helper cells to produce IL-2.
SUMMARY OF THE INVENTION
This invention provides methods of increasing the level of IL-2 produced by T helper cells in a patient infected with a human immunodeficiency virus. The method comprises administering an amount of an antagonist of interleukin 10 wherein said amount is effective to increase the patient's T helper cell production of IL-2. The antagonists are preferably administered intravenously. A preferred antagonist is an antibody specific for binding to IL-10. The antibodies can be chimeric, recombinant, polyclonal or monoclonal. Autologous antibodies, human or humanized antibodies are preferred for safety when human patients are being treated. The preferred single dosage of antibodies is 1-10 mg/kg body weight per antibody. Alternatively the amount of the antibody administered in a single dose is about 10 to about 100 μg per milliliter of patient sera.
DETAILED DESCRIPTION
This invention provides an effective means for increasing production of IL-2 in T helper cells when said levels are being inhibited by excessive levels of IL-10 attendant an infection of lentiviruses known as the human immunodeficiency virus [HIV]. This chronic and often fatal viral infection is typified by an imbalance in T helper cellular responses. The result of this imbalance is an inhibition of IL-2 production by nonvirally infected T helper cells due to excessive levels of IL-10. The IL-10 is produced by a number of different cells including a subset of the T helper cells.
The maintenance of IL-2 production is beneficial to HIV infected patients. IL-2 is responsible for T cell proliferation and is a key indicator of the status of the immune system.
The reduction of IL-2 production can be halted by administration of adequate amounts of antagonists specific for IL-10. Antagonists of IL-10 can be made by mutating the amino acid sequence of IL-10 using standard mutagenesis methods. Such methods include the use of M13 vectors to introduce single site mutations, to delete random amino acids from IL-10 or to add amino acids. The resulting muteins are then tested in standard assays for the ability to compete with nonmutated IL-10. Suitable assays are described below and include in vitro cell assays where IL-2 dependent proliferation is initiated by the presence of exogenous IL-10. This strategy have been used to characterize the functional domains of numerous proteins such as thrombomodulin, human growth factor and tissue plasminogen activator.
Alternatively, the antagonist can be an antibody specific for binding to IL-10 [α IL-10] and which interferes with its binding to the T- helper receptor, α IL-10 is produced in a variety of conventional ways. A general review of antibody production can be found in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Pubs., N.Y. (1988) or in Colligan et al. Eds., 1991 and Suppl. Current Protocols in Immunology, Green Wiley, NY, NY. Antibodies can be a polyclonal mixture or monoclonal. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources. Antibodies also include the immunore active portions of intact immunoglobulins.
In brief, methods to obtain α IL-10 antibodies involve administering an amount of antigen sufficient to induce a humoral response in a mammal. The antibodies are either collected from the mammal's sera or lymphocytes removed, immortalized and those cell clones secreting the desired antibodies isolated and cultured for harvest of the desired antibodies. Antibodies against IL-10 are described by Mosmann et al, 1990 /. Immunol. 145:2938.
These methods require adequate sources of IL-10 as antigens. The antigens can either be intact IL-10 or immunoreactive peptides. Recombinant expression of IL-10 is a convenient means for obtaining IL-10 for use as antigens. For a general review of the applicable recombinant technology see Sambrook, et al, Molecular Cloning - A laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1989. Specific techniques for expressing and purifying IL-10 are known. Expression of IL-10 is described in PCT/US/03554 (WO/91 /00349) and in Malefyt, et al., 1992, Curr. Opin. Immunology, 4:314-320. Alternatively, peptide synthesis may be used to obtain intact or immunoreactive portions of IL-10.
The antibodies for use in this invention are preferably autologous for the patient thereby minimizing further immunological problems. Immunodefiάent individuals will tend to be less reactive to non-self antibodies, and thus non-self antibodies derived from cells of the same species are also useful. Antibodies of different species are useful but means to control possible adverse immi oreactions must be undertaken. For example, humanized rat antibodies can minimize immune responses in human patients.
The antibodies for use in this invention are typically neutralizing antibodies and will preferably have binding constants which are greater than or approximates the affinity of IL-10 for its natural receptor. Antibodies having a binding constant 100-fold less than these cytokines for their corresponding receptors are less preferred. Binding comparisons are carried out using standard equilibrium methods. The basic technology is described in Chapter 25 of Vol. 1: Immunochemistry, Ed. D.M. Weir, 4th Ed. 1986, Blackwell Scientific Publ. 25. 1-25.30. Alternatively, one can use an assay for determining the molar excess of antibody which neutralizes a defined amount of IL-10 in a standard in vitro bioassay. Examples of such assays are found in Mosmann and Fong, 1989, /. Immunol. Methods, 116 : 151 (IL-4) and Fiorentino et ah, 1989, J. Exp. Med. 170 : 2081. A reasonable range are those antibodies which neutralize a given amount of IL-10 in a 10 to 1,000 fold excess.
The means of adiniriistration of the antagonists, e.g. α IL-10 are typically parenteral, preferably intravenous. The antagonists are infused into the patient using standard intravenous techniques. The antagonists are first suspended into a sterile, physiologically-compatible media, such as phosphate buffered saline. Pharmaceutically acceptable excipients such as lecithin, glucose, dextrose, antibiotics may also be included with the antagonists.
When the antagonists are antibodies, they are administered in an amount which provides circulating levels of α IL-10 at about 1 to 150 μg/ml and preferably 10 to 100 μg/ml of sera for each antibody. The antibodies have a 2-7 day half -life and repeated administration is necessary when levels of α IL-10 are below these levels. Total amount of α IL-10 applied per administration are between 1 and 10 mg/kg of body weight for each antibody.
The method will increase IL-2 production and it is preferred that said levels approach or exceed 100% of normal. Increases of greater than 50% of the IL-2 production before treatment are considered good. Treatment can be terminated when the T helper cells are producing levels of IL-2 at 10 to 100% of normal when measured by any number of conventional assays.
These conventional assays fall into two categories. The first category are bioassays that measure IL-2 dependent proliferation of any of several immortal cell lines which proliferate in the presence of IL-2. An example of such a cell line is CTLL. Cell division is measured by radiolabelled thymidine uptake. The second category are functional assays and involve the use of immunoassays directly measuring IL-2 such as ELISA. A general overview of this art can be found in Mosmann and Fong, 1989, Specific assays for cytokine production by T cells, /. Immunol. Meth. 116 : 151-158.
Conventional antiviral therapies such as AZT, may also be used in conjunction with this invention. Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be recognized that certain changes and modifications may be practiced within the scope of the claims.

Claims

WHAT IS CLAIMED IS:
1. A method of increasing the level of T helper cell production of interleukin 2 in a patient infected with a human immunodeficiency virus said method comprising administering an amount of an antagonist of interleukin 10 (IL-10) effective to increase the patient's T helper cell production of IL-2.
2. A method for the manufacture of a pharmaceutical composition for increasing the level of T helper cell production of interleukin 2 in a patient infected with a human immunodeficiency virus comprising admixing an antagonist to IL-10 with a pharmaceutically acceptable carrier.
3. The method of any one of claims 1-2 in which the antagonist is an antibody to IL-10.
4. A pharmaceutical composition for increasing the level of T helper cell production of interleukin 2 in a patient infected with a human immunodeficiency virus comprising an antagonist to IL-10 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 in which the antagonist is an antibody to IL-10.
6. The use of an antagonist to IL-10 for increasing the level of T helper cell production of interleukin 2 in a patient infected with a human immunodeficiency virus.
7. The use of an antagonist to IL-10 for the manufacture of a medicament for increasing the level of T helper cell production of interleukin 2 in a patient infected with a human immunodeficiency virus.
8. The use of either claim 6 or 7 in which the antagonist to IL-10 is an antibody to IL-10.
EP93921492A 1992-09-18 1993-09-16 Restoration of immunocompetency to t helper cells in hiv infected patients Withdrawn EP0667789A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94731692A 1992-09-18 1992-09-18
US947316 1992-09-18
PCT/US1993/008562 WO1994006473A1 (en) 1992-09-18 1993-09-16 Restoration of immunocompetency to t helper cells in hiv infected patients

Publications (1)

Publication Number Publication Date
EP0667789A1 true EP0667789A1 (en) 1995-08-23

Family

ID=25485948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921492A Withdrawn EP0667789A1 (en) 1992-09-18 1993-09-16 Restoration of immunocompetency to t helper cells in hiv infected patients

Country Status (6)

Country Link
EP (1) EP0667789A1 (en)
JP (1) JPH08501549A (en)
AU (1) AU4856793A (en)
CA (1) CA2144648A1 (en)
MX (1) MX9305713A (en)
WO (1) WO1994006473A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529026C2 (en) * 1995-07-28 1997-06-19 Robert Sabat Monoclonal antibodies against human interleukin-10
AU6887096A (en) * 1996-09-11 1998-04-02 Patrick T. Prendergast Immune direction therapy
DE19939653A1 (en) * 1999-08-13 2001-02-22 Thomas Huenig Use of CD28 specific monoclonal antibodies for the production of a pharmaceutical composition
MXPA03002278A (en) 2000-09-14 2004-12-03 Beth Israel Hospital Modulation of il-2- and il-15-mediated t cell responses.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
ES2138976T3 (en) * 1991-08-06 2000-02-01 Schering Corp USE OF INTERLEUKIN-10 ANALOGS OR ANTAGONISTS TO TREAT ENDOTOXIN OR SUPERANTIGEN INDUCED TOXICITY.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9406473A1 *

Also Published As

Publication number Publication date
MX9305713A (en) 1994-05-31
JPH08501549A (en) 1996-02-20
AU4856793A (en) 1994-04-12
WO1994006473A1 (en) 1994-03-31
CA2144648A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
AU689236B2 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Seder et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.
Trembleau et al. Deviation of pancreas‐infiltrating cells to Th2 by interleukin‐12 antagonist administration inhibits autoimmune diabetes
Weaver et al. T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.
AU690557B2 (en) New therapeutic, anti-proteic mediator kits, a process for their preparation and pharmaceutical compositions containingthem
US20150376278A1 (en) Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect
US8012475B2 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Debets et al. Cytokine antagonists and their potential therapeutic use
Chaturvedi et al. Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells
Rizzo et al. Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo
Prümmer Treatment-induced antibodies to interleukin-2
EP0667789A1 (en) Restoration of immunocompetency to t helper cells in hiv infected patients
KR100333148B1 (en) Soluble T-cell receptor α chains and derivatives containing Vα 14Jα 281 used as a preventive and therapeutic agent for diabetes diseases
JPH07563B2 (en) Drug for the prevention or sedation of eosinophilia
CZ281796B6 (en) The use of interleukin-10 or analog, agonist or antagonist thereof and pharmaceutical composition containing thereof
Cunningham-Rundles et al. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency
JP3138481B2 (en) Use of IL-7 for the treatment of autoimmune diseases and especially insulin-dependent diabetes
Ajitsu et al. In vivo immunologic intervention in age-related T cell defects in murine gut-associated lymphoid tissues by IL2
WO1996040966A1 (en) Compositions and methods of treating il-6 associated diseases
Romball et al. Cytokines in the induction and circumvention of peripheral tolerance
CARLA RE et al. Hyperimmunoglobulinemia in HIV-1 infected individuals does not clearly correlate with plasma levels of IL-6
JPH05117163A (en) Medicinal preparation for maturation of prothymocyte
JPH08245414A (en) Composition and method for medical treatment of il-6 related disease
WO1991015236A1 (en) Treatment of autoimmune diseases
WO1991012330A1 (en) Production of immunosuppressive factor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970401